Ursodeoxycholic acid: unique properties and clinical applications

熊去氧胆酸 胆汁淤积 胆盐出口泵 胆汁酸 化学 生物化学 分泌物 原发性硬化性胆管炎 G蛋白偶联胆汁酸受体 运输机 内科学 医学 基因 疾病
作者
M. V. Maevskay
出处
期刊:Медицинский совет [REMEDIUM GROUP LLC]
卷期号: (8): 96-105 被引量:2
标识
DOI:10.21518/ms2023-136
摘要

Ursodeoxycholic acid (UDCA) is a natural hydrophilic bile acid, which is present in humans as a small fraction of the total amount of bile acids (5%). Its unique properties underlie its use in a number of liver diseases as a first-line therapy. The ability of UDCA to reduce the secretion of cholesterol into bile, form mixed micelles (liquid crystals) with cholesterol molecules and interact with multifunctional nuclear receptors, are actively used in the treatment and prevention of cholelithiasis. UDCA has the ability to stimulate hepatobiliary secretion, promotes the secretion of bicarbonate by cholangiocytes, which is relevant for patients with primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). UDCA activates transporter proteins such as bile acid export pump (BSEP), multiresistance protein 2 (MRP2) – conjugates transporter, type 2 anion exchanger (AE2), and promotes their movement to the canalicular membrane of cells. UDCA acts as a pleiotropic agent that plays a unique role in modulating the classical mitochondrial pathway of apoptosis in various cell types. Double molecular bonds of UDCA serve as a trap for free radicals, which suppresses the processes of lipid peroxidation. The ability of UDCA to penetrate into mitochondrial membranes leads to suppression of the activity of mitochondrial oxidase enzymes responsible for the production of superoxide anion. UDCA activates autophagy and promotes the elimination of toxic fatty acids from hepatocytes, reducing liver steatosis, UDCA has anti-inflammatory, antifibrotic, immunomodulatory and anticarcinogenic effects. UDCA is included in international and Russian clinical guidelines for the treatment of patients with various liver diseases (PBC, PSC, intrahepatic cholestasis of pregnancy, drug-induced cholestasis, alcoholic liver disease with cholestatic component), cholelithiasis, cystic fibrosis. In the pharmacotherapy of non-alcoholic fatty liver disease, UDCA is the only drug that has a bi-directional effect on the liver and cardiovascular system.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆应助qianzhihe采纳,获得10
3秒前
小二郎应助xfyxxh采纳,获得10
4秒前
perovskite完成签到,获得积分20
4秒前
yang完成签到,获得积分10
4秒前
4秒前
Maisie完成签到,获得积分10
5秒前
丘比特应助聪明藏今采纳,获得10
6秒前
Grace159完成签到 ,获得积分10
7秒前
chenjzhuc应助科研通管家采纳,获得10
7秒前
7秒前
乐乐应助科研通管家采纳,获得10
7秒前
tuanheqi应助科研通管家采纳,获得150
7秒前
7秒前
Orange应助科研通管家采纳,获得10
7秒前
科研通AI2S应助科研通管家采纳,获得10
7秒前
六六应助科研通管家采纳,获得10
7秒前
浮游应助科研通管家采纳,获得10
7秒前
我是老大应助科研通管家采纳,获得10
8秒前
浮游应助科研通管家采纳,获得10
8秒前
科研通AI6应助科研通管家采纳,获得10
8秒前
英姑应助科研通管家采纳,获得10
8秒前
CipherSage应助科研通管家采纳,获得10
8秒前
科目三应助科研通管家采纳,获得10
8秒前
小杭76应助科研通管家采纳,获得10
8秒前
8秒前
tianliyan完成签到,获得积分10
11秒前
研友_VZG7GZ应助perovskite采纳,获得10
12秒前
量子星尘发布了新的文献求助10
12秒前
我是老大应助听白采纳,获得10
12秒前
xiaoxiao完成签到 ,获得积分10
13秒前
13秒前
小二郎应助黄佳慧采纳,获得10
13秒前
tianliyan发布了新的文献求助10
15秒前
16秒前
17秒前
17秒前
kaka22发布了新的文献求助10
18秒前
xfyxxh发布了新的文献求助10
19秒前
25秒前
善学以致用应助一年5篇采纳,获得10
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Acute Mountain Sickness 2000
Cowries - A Guide to the Gastropod Family Cypraeidae 1200
Handbook of Milkfat Fractionation Technology and Application, by Kerry E. Kaylegian and Robert C. Lindsay, AOCS Press, 1995 1000
Textbook of Neonatal Resuscitation ® 500
Why Neuroscience Matters in the Classroom 500
The Affinity Designer Manual - Version 2: A Step-by-Step Beginner's Guide 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5049873
求助须知:如何正确求助?哪些是违规求助? 4277679
关于积分的说明 13334372
捐赠科研通 4092479
什么是DOI,文献DOI怎么找? 2239723
邀请新用户注册赠送积分活动 1246498
关于科研通互助平台的介绍 1175214